Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder

a head-to-head, randomized, double-blind, phase IIIb study

Ralf W. Dittmann (Lead / Corresponding author), Esther Cardo, Peter Nagy, Colleen S. Anderson, Ralph Bloomfield, Beatriz Caballero, Nicholas Higgins, Paul Hodgkins, Andrew Lyne, Richard Civil, David Coghill

    Research output: Contribution to journalArticle

    50 Citations (Scopus)

    Abstract

    The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).
    Original languageEnglish
    Article numbern/a
    Number of pages12
    JournalCNS Drugs
    Volumen/a
    DOIs
    Publication statusPublished - 20 Aug 2013

    Fingerprint

    Methylphenidate
    Prodrugs
    Attention Deficit Disorder with Hyperactivity
    Safety
    Therapeutics
    Lisdexamfetamine Dimesylate
    Atomoxetine Hydrochloride

    Cite this

    Dittmann, Ralf W. ; Cardo, Esther ; Nagy, Peter ; Anderson, Colleen S. ; Bloomfield, Ralph ; Caballero, Beatriz ; Higgins, Nicholas ; Hodgkins, Paul ; Lyne, Andrew ; Civil, Richard ; Coghill, David. / Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder : a head-to-head, randomized, double-blind, phase IIIb study. In: CNS Drugs. 2013 ; Vol. n/a.
    @article{693a190ce637428ba2818dcaa6b59138,
    title = "Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study",
    abstract = "The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).",
    author = "Dittmann, {Ralf W.} and Esther Cardo and Peter Nagy and Anderson, {Colleen S.} and Ralph Bloomfield and Beatriz Caballero and Nicholas Higgins and Paul Hodgkins and Andrew Lyne and Richard Civil and David Coghill",
    year = "2013",
    month = "8",
    day = "20",
    doi = "10.1007/s40263-013-0104-8",
    language = "English",
    volume = "n/a",
    journal = "CNS Drugs",
    issn = "1172-7047",
    publisher = "Springer Verlag",

    }

    Dittmann, RW, Cardo, E, Nagy, P, Anderson, CS, Bloomfield, R, Caballero, B, Higgins, N, Hodgkins, P, Lyne, A, Civil, R & Coghill, D 2013, 'Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study', CNS Drugs, vol. n/a, n/a. https://doi.org/10.1007/s40263-013-0104-8

    Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder : a head-to-head, randomized, double-blind, phase IIIb study. / Dittmann, Ralf W. (Lead / Corresponding author); Cardo, Esther; Nagy, Peter; Anderson, Colleen S.; Bloomfield, Ralph; Caballero, Beatriz; Higgins, Nicholas; Hodgkins, Paul; Lyne, Andrew; Civil, Richard; Coghill, David.

    In: CNS Drugs, Vol. n/a, n/a, 20.08.2013.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder

    T2 - a head-to-head, randomized, double-blind, phase IIIb study

    AU - Dittmann, Ralf W.

    AU - Cardo, Esther

    AU - Nagy, Peter

    AU - Anderson, Colleen S.

    AU - Bloomfield, Ralph

    AU - Caballero, Beatriz

    AU - Higgins, Nicholas

    AU - Hodgkins, Paul

    AU - Lyne, Andrew

    AU - Civil, Richard

    AU - Coghill, David

    PY - 2013/8/20

    Y1 - 2013/8/20

    N2 - The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).

    AB - The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).

    U2 - 10.1007/s40263-013-0104-8

    DO - 10.1007/s40263-013-0104-8

    M3 - Article

    VL - n/a

    JO - CNS Drugs

    JF - CNS Drugs

    SN - 1172-7047

    M1 - n/a

    ER -